BioCardia, Inc. (NASDAQ:BCDA) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Miranda Peto - Investor Relations Peter Altman - President and CEO David McClung - Chief Financial Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Laura Suriel - Alliance Global Partners Kevin Marshall - Innovative Financial Group Operator Ladies and gentlemen, thank you for standing by. Good afternoon. And welcome to the BioCardia Second Quarter 2024 Financial Results and Busi ...

SUNNYVALE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2024 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2024 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. ...

Exhibit 99.1 BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results Sunnyvale, Calif. – August 13, 2024 - BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2024 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2024 with the Securities and Exchange Commission. The Company will also hold a conf ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38999 BioCardia, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2753988 (State or another jurisdiction of incorporation or organization) ...

Core Insights - BioCardia, Inc. has submitted a 510(k) application for its Morph® DNA™ Steerable Introducer Sheath, aimed at enhancing the introduction of medical instruments into the vascular system [1][2] - The Morph DNA technology has already been utilized in previously approved products, including the Helix biotherapeutic delivery Morph DNA guide system and the Avance transseptal steerable introducer [2] - The potential market for the new product family encompasses millions of procedures annually, including various cardiac and peripheral vascular interventions [3] Company Overview - BioCardia, Inc. is focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, with its main product platforms being CardiAMP® and CardiALLO™ [4] - The company has three clinical stage product candidates in development, supported by its Helix biotherapeutic delivery and Morph vascular navigation platforms [4] Product Details - The Morph DNA design allows for improved catheter performance by enabling tensioning elements to rotate around the catheter shaft, which aids in navigation and reduces mechanical "whip" [2] - The new introducer sheath is designed to accommodate a wide range of sizes and lengths for various complex clinical procedures, aligning with the company's mission to advance therapeutic solutions [3]

Core Insights - BioCardia, Inc. has been granted Patent No: 12,036,371 for a method of accessing the left atrium with a multi-directional steerable catheter, which will expire in 2035, enhancing shareholder value [1][2][3] Company Overview - BioCardia is focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, with its key product platforms being CardiAMP® and CardiALLO™ [4] Market Insights - The transseptal access systems market generated $941.3 million in revenue in 2022 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 7.3%, reaching $2.1 billion by 2033 [2][7] - The Morph DNA technology allows for improved catheter performance and navigation, addressing a longstanding technical issue in transseptal procedures [2][3] Product Development - BioCardia plans to utilize the new introducer technology platform for various biotherapeutic interventions, including heart failure and acute myocardial infarction treatments, targeting approximately 500,000 transseptal procedures performed annually in the U.S. [3]

Core Insights - BioCardia, Inc. has been granted Patent No: 12,036,371 for a method of accessing the left atrium with a multi-directional steerable catheter, which will expire in 2035, enhancing shareholder value [1][2][3] Company Overview - BioCardia is focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, with its biotherapeutic platforms including CardiAMP® and CardiALLO™ [4] Market Insights - The transseptal access systems market generated $941.3 million in revenue in 2022 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 7.3%, reaching $2.1 billion by 2033 [2][7] - The Morph DNA technology allows for improved catheter performance and navigation, addressing a longstanding technical issue in transseptal procedures [2][3] Product Development - BioCardia plans to utilize the new introducer technology platform for various biotherapeutic interventions related to heart failure, refractory angina, and acute myocardial infarction, targeting approximately 500,000 transseptal procedures performed annually in the U.S. [3]

MULHOUSE, France, and SUNNYVALE, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announce success from a collaborative Phase II trial of ProtheraCytes for the treatment of acute myocardial infarction (AMI) led by CellProthera, as well as plans to continue the re ...

SUNNYVALE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the Unites States Patent Office has granted Patent No: 11,986,611 titled “Radial and Transendocardial Delivery Catheter,” with a patent term that will expire in 2036.   The present invention relates to medical methods and systems suitable for substance delivery to the heart via a radi ...

SUNNYVALE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the Unites States Patent Office has granted Patent No: 11,986,611 titled "Radial and Transendocardial Delivery Catheter," with a patent term that will expire in 2036.   The present invention relates to medical methods and systems suitable for substance delivery to the heart via a radia ...